These data demonstrate that the acetylation of SMAD3 promotes its interaction with oncogenic TRIM24 and reduces its association with TRIM33 tumor suppressor, leading to enhanced SMAD3 oncogenic activity. This evidence concerns the gene SMAD3 and neoplasm.